Apart from ibrutinib, clients with M-CLL, devoid of TP53 aberrations and fit sufficient to tolerate FCR therapy, should be superior candidates for that latter, with the benefit becoming that this therapy could be done in six months though ibrutinib has to be taken indefinitely. This feature could well be notably important for non-compliant people o